A Phase 2, Global, Multicenter, Long-term Safety Study Designed to Assess the Safety and Tolerability of BHV-7000 in Subjects with Refractory Focal Onset Epilepsy

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508813-18-00

Acronym

BHV7000-201

Enrollment

377

Registered

2024-10-07

Start date

2024-12-18

Completion date

Unknown

Last updated

2025-09-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory Focal Onset Epilepsy

Brief summary

Safety is assessed by the number of unique subjects with deaths, SAE’s, AE’s leading to discontinuation, moderate and severe AEs and grade 3 and 4 laboratory abnormalities

Interventions

DRUGBHV-7000

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Safety is assessed by the number of unique subjects with deaths, SAE’s, AE’s leading to discontinuation, moderate and severe AEs and grade 3 and 4 laboratory abnormalities	—

Countries

Austria, Belgium, Croatia, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, Italy, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026